Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Rakesh K. Singh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1317-3520; OpenAlex author ID A5033322099; NIH RePORTER profile ID 1859729. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 9)
Trials
0
Grants
2
Labs led
2
Collaborators
24
Papers, trials and grants by year

2015: 1 grant · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 grant · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 13

  1. Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.1096/fba.2025-00265↗
  2. Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer. Last author DOI 10.3390/cancers17213541↗
  3. Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. Last author DOI 10.1016/j.canlet.2023.216185↗
  4. Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis. Last author DOI 10.1016/j.ajpath.2021.01.002↗
  5. Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2021.03.028↗
  6. Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer. Last author DOI 10.3390/cancers13040818↗
  7. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy. Co-author DOI 10.1021/acsnano.9b03978↗
  8. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Last author DOI 10.1096/fj.201902990r↗
  9. Cancer-Associated Fibroblasts' Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers11030290↗
  10. Semaphorin-5A maintains epithelial phenotype of malignant pancreatic cancer cells. Last author DOI 10.1186/s12885-018-5204-x↗
  11. Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. Last author DOI 10.18632/oncotarget.23644↗
  12. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. Co-author DOI 10.1016/j.pharmthera.2017.05.012↗
  13. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer. Last author DOI 10.18632/oncotarget.6906↗

Grants 2

  1. Targeting CXCR2 axis in Pancreatic Cancer R01CA228524↗
  2. Rapid Autopsy Program U54CA163120↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 6 shared papers, 2 shared grants, 2015–2026 · strength 1.66
  2. Sugandha Saxena · 7 shared papers, 2018–2026 · strength 1.04
  3. Caitlin Molczyk · 3 shared papers, 2023–2026 · strength 0.77
  4. Reegan Sturgeon · 3 shared papers, 2023–2026 · strength 0.77
  5. Abhilasha Purohit · 6 shared papers, 2016–2023 · strength 0.69
  6. Dipakkumar R. Prajapati · 5 shared papers, 2020–2023 · strength 0.66
  7. Michael Anthony Hollingsworth · 3 shared papers, 1 shared grant, 2015–2025 · strength 0.63
  8. Paul M. Grandgenett · 2 shared papers, 2021–2025 · strength 0.41
  9. Mohammad I. Awaji · 3 shared papers, 2018–2020 · strength 0.38
  10. Satyanarayana Rachagani · 4 shared papers, 2016–2021 · strength 0.37
  11. Namita Bhyravbhatla · 1 shared paper, 2026 · strength 0.30
  12. Rick Bhatia · 1 shared paper, 2026 · strength 0.30
  13. Sushil Kumar · 1 shared paper, 2026 · strength 0.30
  14. David Oupický · 3 shared papers, 2017–2021 · strength 0.30
  15. Sushil Kumar K · 2 shared papers, 2020–2023 · strength 0.29
  16. Ying Xie · 2 shared papers, 2020–2021 · strength 0.22
  17. Hang Yu · 2 shared papers, 2020–2021 · strength 0.22
  18. Pranita Atri · 2 shared papers, 2018–2021 · strength 0.20
  19. Richard L. Sleightholm · 2 shared papers, 2017–2020 · strength 0.18
  20. Keith R Johnson · 1 shared grant, 2015 · strength 0.14
  21. Siyuan Tang · 1 shared paper, 2021 · strength 0.12
  22. David Větvička · 1 shared paper, 2021 · strength 0.12
  23. Maneesh Jain · 1 shared paper, 2020 · strength 0.10
  24. Michel M. Ouellette · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.